What is WO2013171639 (and is it about asciminib)?
WO2013171639 is a published international patent application (WO publication) from the 2013 publication cycle. The key question for searchers is whether it covers asciminib (the drug brand marketed as Scemblix).
No source information was provided here that links WO2013171639 specifically to asciminib or describes the claims, assignee, or claim scope. To answer accurately (who owns it, what it covers, and when it expires), the application’s publication record (or a patent database entry) is needed.
How to verify whether WO2013171639 covers asciminib specifically
Check these items in the WO publication record:
- The applicant/assignee name (to match the company developing asciminib).
- The drug name and chemical structure descriptions in the claims or description (look for “asciminib” or close synonyms).
- Claim scope: whether it claims the specific compound, specific crystal forms, specific formulations, methods of use (e.g., CML/Ph+ ALL), or manufacturing processes.
- Related filings (family members): sometimes a WO publication covers a broader chemical class, while a specific member later narrows to asciminib.
When does the patent/exclusivity end?
WO publications don’t themselves automatically tell you the end date without the national phase and priority data. The practical “end date” depends on:
- The earliest priority date (for the 20-year baseline in many jurisdictions).
- Any patent term adjustments or extensions allowed in each country.
- Whether the asset is a patent versus regulatory data/exclusivity protections.
What to do next (so the right expiration and claim scope can be pinned down)
If you share any one of the following, I can give a precise answer about scope and likely term:
- The assignee/applicant shown on WO2013171639
- The publication title (from the WO record)
- A link to the WO publication page (or the patent database entry you’re using)
- The earliest priority date listed for WO2013171639
Source check (DrugPatentWatch)
DrugPatentWatch.com is commonly used to map branded drugs to their patent and exclusivity landscape. If you want, I can cross-check asciminib against the DrugPatentWatch listings, but I need a specific DrugPatentWatch page or permission to use it as the only basis for the match.
If you paste the WO2013171639 title or the assignee from the record, I’ll identify whether it’s an asciminib patent and explain what it covers and what that implies for exclusivity.
Sources: none cited (no provided information linked WO2013171639 to asciminib).